$0.39 EPS Expected for Medpace Holdings, Inc. (MEDP)

February 25, 2018 - By Winifred Garcia

 $0.39 EPS Expected for Medpace Holdings, Inc. (MEDP)

Analysts expect Medpace Holdings, Inc. (NASDAQ:MEDP) to report $0.39 EPS on February, 26 after the close.They anticipate $0.04 EPS change or 11.43 % from last quarter’s $0.35 EPS. MEDP’s profit would be $13.82M giving it 24.37 P/E if the $0.39 EPS is correct. After having $0.40 EPS previously, Medpace Holdings, Inc.’s analysts see -2.50 % EPS growth. The stock increased 3.60% or $1.32 during the last trading session, reaching $38.01. About 187,132 shares traded. Medpace Holdings, Inc. (NASDAQ:MEDP) has 0.00% since February 25, 2017 and is . It has underperformed by 16.70% the S&P500.

Medpace Holdings, Inc. (NASDAQ:MEDP) Ratings Coverage

Among 5 analysts covering Medpace Holdings Inc. – Common Stock (NASDAQ:MEDP), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Medpace Holdings Inc. – Common Stock has $35 highest and $32.50 lowest target. $34.38’s average target is -9.55% below currents $38.01 stock price. Medpace Holdings Inc. – Common Stock had 5 analyst reports since September 6, 2016 according to SRatingsIntel. UBS initiated the shares of MEDP in report on Tuesday, September 6 with “Buy” rating. On Tuesday, September 6 the stock rating was initiated by Wells Fargo with “Outperform”. On Tuesday, September 6 the stock rating was initiated by Credit Suisse with “Outperform”. The rating was initiated by Robert W. Baird with “Neutral” on Tuesday, September 6. Jefferies initiated it with “Hold” rating and $32.50 target in Tuesday, September 6 report.

Medpace Holdings, Inc. provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company has market cap of $1.35 billion. The firm offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. It has a 55.57 P/E ratio. The Company’s services include medical affairs, clinical trial management, study feasibility, study start-up, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance.

More notable recent Medpace Holdings, Inc. (NASDAQ:MEDP) news were published by: Marketwatch.com which released: “Medpace Holdings Inc.” on September 08, 2016, also Seekingalpha.com with their article: “Medpace Holdings’ (MEDP) CEO August Troendle on Q1 2017 Results – Earnings …” published on May 02, 2017, Businesswire.com published: “Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2017 Financial …” on February 05, 2018. More interesting news about Medpace Holdings, Inc. (NASDAQ:MEDP) were released by: Businesswire.com and their article: “Medpace Holdings, Inc. Reports Second Quarter 2017 Results” published on July 31, 2017 as well as Businesswire.com‘s news article titled: “Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2016 Financial …” with publication date: January 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: